Healthcare Industry News: HSMN NewsFeed
News Release - March 28, 2017
Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal OfficerHERTFORDSHIRE, England and PITTSBURGH, March 28, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Daniel M. Gallagher as chief legal officer. He will be joining the company on April 17, 2017.
Gallagher joins Mylan from Patomak Global Partners, a consulting firm providing strategic advice, compliance consulting, and litigation and regulatory enforcement services, where he was president. From Nov. 2011 to Oct. 2015, Gallagher served as a commissioner of the U.S. Securities and Exchange Commission (SEC). During his tenure at the SEC, he focused on initiatives aimed at strengthening the U.S. capital markets and encouraging capital formation. As commissioner, he called for reform on various corporate governance issues, advocated for conducting a comprehensive holistic review of equity market structure issues, and encouraged building the Commission's fixed income market expertise.
Before being appointed commissioner, Gallagher served on the staff of the SEC in several capacities, including as counsel to both SEC Commissioner Paul Atkins and Chairman Christopher Cox, working on matters involving the Division of Enforcement and the Division of Trading and Markets. Gallagher served as deputy director and co-acting director of the Division of Trading and Markets from 2008 to 2010, where he was on the front lines of the agency's response to the financial crisis, including representing the Commission in the Lehman Brothers liquidation.
Mylan CEO Heather Bresch commented, "Dan is an exceptional lawyer with a distinguished career in both public service and the private sector. In addition to his keen legal intellect and outstanding reputation, Dan's extensive experience in regulatory matters, financial markets, and corporate legal affairs and governance will add significant value to our senior leadership team and add further depth to Mylan's already strong legal organization. We believe that the various transformations underway across the global healthcare industry, most notably in the U.S., as well as Mylan's own continued evolution into a global healthcare company, will create significant opportunities for us going forward and Dan will be valuable in helping us to maximize these opportunities."
Gallagher commented, "Mylan has enjoyed remarkable growth during a very short period and has become a global powerhouse in the generic and specialty pharmaceutical industry. I have had the opportunity to get to know the company well over the last couple of years and believe Mylan is uniquely positioned in the industry as a result of its clear and compelling vision and strategy, unmatched global assets, strong culture and unwavering commitment to doing what is right. I am excited to join Mylan's leadership team at this time in the company's evolution and am honored to lead the company's world-class legal organization in support of Mylan's future success."
In addition to his tenure in public service, Gallagher spent a number of years in the private sector. Following law school, he joined the Washington, D.C. law firm Wilmer Cutler & Pickering, where he advised clients on broker-dealer regulatory issues and represented clients in SEC and SRO enforcement proceedings. He later returned to Wilmer (now WilmerHale) as a partner following his staff service at the SEC. Gallagher also served as senior vice president and general counsel of Fiserv Securities, Inc., where he was responsible for managing all of the firm's legal and regulatory matters.
Gallagher received his B.A. in English from Georgetown University and his J.D., magna cum laude, from the Catholic University of America, where he was a member of the Law Review.
Gallagher serves as non-executive director of both the Irish Stock Exchange and Symbiont.io, and is on the advisory board of the Drexel LeBow Center for Corporate Governance.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We market a growing portfolio of approximately 7,500 products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus(R) Patents
Mylan and Aspen Announce Launch of Generic Busulfex(R) Injection
FDA approves first biosimilar for the treatment of certain breast and stomach cancers